Clear Harbor Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Clear Harbor Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,600	Closed	-$46K	–	405
2022 Q2	$46K	Buy	15,600 +5,000	+47%	+$11.9K	0.01%	383
2022 Q1	$33K	Hold	10,600	–	–	﹤0.01%	392
2021 Q4	$36K	Sell	10,600 -1,500	-12%	-$5.7K	﹤0.01%	408
2021 Q3	$44K	Hold	12,100	–	–	﹤0.01%	378
2021 Q2	$53K	Sell	12,100 -900	-7%	-$3.99K	0.01%	363
2021 Q1	$59K	Buy	+13,000	New	+$70K	0.01%	332

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Clear Harbor Asset Management's CBAY Position: Q3 2022 in Review

Clear Harbor Asset Management sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 15,600 shares — an estimated $46K sold.

Clear Harbor Asset Management first reported a position in CBAY in Q1 2021 and held it in 6 quarters. The position peaked at $59K in Q1 2021. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

Clear Harbor Asset Management reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
Clear Harbor Asset Management sold 15,600 Cymabay Therapeutics shares in Q3 2022, an estimated $46K.
Clear Harbor Asset Management first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 6 quarters.
Clear Harbor Asset Management's Cymabay Therapeutics position peaked at $59K in Q1 2021.
100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Clear Harbor Asset Management's 13F filing for Q3 2022, filed 25 Oct 2022.